Disse sidene inneholder informasjon som er beregnet på helsepersonell

Du forlater nå hjernenett.no

Protected: Digital produktpresentasjon av Brintellix®

There is no excerpt because this is a protected post.

Les mer: bivirkningsrapportering

 

Les mer: Brintellix® SPC

 

NO-BRIN-0143-2021.10

  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. DSM-5. Washington DC. American Psychiatric Publishing 2013.

  2. Brintellix® SPC 09.2021, avsnitt 4.1

  3. Goodwin GM, Price J, De Bodikant C et al. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017;221:31–35.

  4. Jacobsen PL, Mahableshwarkar AR, Chen Y et al. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036–48.

  5. Serretti A, Mandelli L. Antidepressants and body weight; A comprehensive review and meta-analysis. J Clin Psych. 2010;71(10):1259-72.

  6. Montgomery SA, Nielsen RZ, Poulsen LH et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470-82.

  7. Brintellix® SPC 09/2021, avsnitt 5.1.

  8. Bang-Andersen B, Ruhland T, Jørgensen M et al. Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206-21.

  9. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57.

  10. de Groote, L, Klompmakers AA, Olivier B et al. Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade. Psychopharmacology. 2003;167(2):153-8.

  11. Dremencov, E, El Mansari M, Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci. 2009;34:223-9.

  12. 12. El Mansari M, Guiard BP, Chernoloz O et al. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010;16:e1-17. doi: 10.1111/j.1755-5949.2010.00146.x.

  13. Jackson D, Stachowiak MK, Bruno JP et al. Inhibition of striatal acetylcholine release by endogenous serotonin. Brain Res. 1988;457:259-66.

  14. Kawahara Y, Kawahara H, Kaneko F et al. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology. 2007;194:73-81.

  15. Szabo ST, de Montigny C, Blier P et al. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2000; Mar;3:1-11

  16. West CHK, Ritchie JC, Boss-Williams KA et al. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol. 2009;12:627-41.

  17. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15: 589-600.

  18. Brintellix® SPC 07/2020, avsnitt 5.1 2.

  19. Baldwin DS, Chrones L, Florea I et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology. 2016, Vol. 30(3):242–52.

  20. Boulenger JP, Loft H, Florea I et al. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major Depressive disorder. Journal of Psychopharmacology. 2012:11:1408-16.

  21. Brintellix® SPC 09.2021, avsnitt 4.2.

  22. Brintellix® SPC 09/2021, avsnitt 4.1, 4.2, 4.8, 5.1.

  23. Brintellix® SPC 09.2021, avsnitt 4.8.

  24. Brintellix® SPC 09.2021, avsnitt 4.8, 5.1.

  25. Brintellix® SPC 09.2021, avsnitt 4.5.

Dato publisert 15.04.2021